Brixadi is a prescription medication that contains buprenorphine, an opioid agonist-antagonist. To understand what this means, it helps to know that buprenorphine works differently in your body than full opioids like heroin or prescription painkillers. It attaches to the same receptors in your brain that opioids target, but it does so in a way that produces a milder effect. This quality makes it useful for people managing opioid use disorder—the condition where someone has developed a pattern of opioid use that interferes with their health, work, relationships, or other important areas of life.
Learn About Paying Your FGUA Bill Online →
What sets Brixadi apart from other buprenorphine products is its delivery method. Brixadi comes as a long-acting injection that you receive under the skin, typically once a month or once every three months, depending on the specific formulation your healthcare provider prescribes. This is different from daily tablets or films that dissolve under your tongue. The injection slowly releases medication into your bloodstream over weeks, maintaining steady levels rather than the ups and downs that come with daily dosing.
The medication works by reducing cravings for opioids and blocking the high that would occur if you used opioids while taking it. This dual action—craving reduction plus blockade—makes it harder to fall back into opioid use patterns. The steady delivery through injections removes the daily decision-making about whether to take medication, which appeals to many people trying to maintain their treatment plan.
When buprenorphine reaches your brain, it binds strongly to opioid receptors but doesn't fully activate them the way heroin or pain pills do. This partial activation creates a "ceiling effect," meaning that even if you take too much, the effects plateau rather than continuing to increase. That's why buprenorphine products have a lower overdose risk compared to full opioids, though overdose is still possible, particularly if combined with other substances like alcohol or benzodiazepines.
Practical Takeaway: Brixadi is a monthly or quarterly injection containing buprenorphine that reduces opioid cravings and blocks opioid effects. Its main difference from other buprenorphine products is the injection format and longer time between doses, which some people find easier to manage than daily medications.
Brixadi received FDA approval in December 2023, making it a relatively new addition to the opioid use disorder treatment landscape. This approval came after several years of clinical trials testing both its safety and its ability to treat opioid use disorder effectively. Understanding the approval process helps explain why new medications like this one become available and what level of testing they undergo before reaching patients.
Free Guide to Pay by Plate Illinois Billing →
Before Brixadi itself was tested in humans, years of laboratory and animal research established that buprenorphine in long-acting injection form could be stable and effective. Clinical trials then enrolled hundreds of people with opioid use disorder across multiple sites. These trials measured key outcomes: how many people stayed in treatment, how many used opioids while taking the medication, and what side effects occurred. The FDA reviewed all this data to decide whether Brixadi was safe and effective enough to approve.
The approval specifically covers treatment of moderate-to-severe opioid use disorder in adults. The FDA process doesn't determine whether an individual person should receive the medication—that's a decision made between a patient and their healthcare provider based on individual circumstances. What the approval does mean is that the medication has met federal standards for manufacturing quality, safety, and effectiveness for its stated purpose.
Following approval, the medication entered wider use, and healthcare systems began integrating it into their opioid treatment programs. Real-world outcomes data is still being collected as more people receive the medication. This ongoing information helps the medical community understand how Brixadi performs in actual practice settings rather than controlled research environments. Doctors continue to learn about which patients benefit most and under what conditions.
Practical Takeaway: Brixadi was FDA-approved in late 2023 after clinical trials demonstrated safety and effectiveness for moderate-to-severe opioid use disorder. The approval is based on research evidence but doesn't determine whether any individual person should receive it.
Brixadi comes in two main dosing schedules: a monthly injection and a quarterly (every three months) injection. The choice between these depends on your specific situation, how you respond to treatment, and what your healthcare provider recommends. Starting with the monthly version is more common, since it allows for closer monitoring and more frequent adjustments if needed during the early weeks of treatment.
Free Guide to Mold Removal Methods for Walls →
The monthly formulation comes in doses of 8 mg, 16 mg, and 24 mg. The quarterly version comes in 64 mg, 96 mg, and 128 mg strengths—these higher numbers reflect the larger total amount needed to last three months. Your provider will determine which dose makes sense based on your history of opioid use, any other medications you take, and how your body responds to treatment. Someone with a long history of heavy opioid use might need a higher dose than someone with recent, lighter use.
Most people don't start at their final maintenance dose. Instead, treatment usually begins with an induction phase where you may take a dose of sublingual (under-the-tongue) buprenorphine first to make sure you tolerate it well. After this initial period—sometimes just a few days—you transition to the first Brixadi injection. The weeks following that first injection are critical for monitoring how you respond. Healthcare providers watch for signs that the dose is working (reduced cravings, no opioid use) or whether adjustments are needed.
The transition from monthly to quarterly dosing typically happens after you've been stable on the monthly version for at least several months. "Stable" means you're attending appointments, not using opioids, and not experiencing problematic side effects. If you switch to quarterly injections, your provider calculates the appropriate dose—it's not simply three times the monthly amount, but rather a specially formulated dose designed for longer-acting release.
Throughout treatment, you'll have regular check-ins with your healthcare provider. These visits involve discussing how you're feeling, any cravings or opioid use, side effects, and life circumstances. Some programs include urine testing to verify medication compliance and confirm abstinence from opioids. Others use less frequent monitoring if you're doing well. The frequency and intensity of monitoring varies by program and individual need.
Practical Takeaway: Brixadi dosing starts monthly with potential for switching to quarterly injections after stability. Treatment begins with an induction phase, followed by regular monitoring and potential dose adjustments based on how you respond and your opioid use patterns.
Like all medications, Brixadi can cause side effects, though not everyone experiences them equally. The most commonly reported side effects during clinical trials were injection site reactions—redness, pain, itching, or swelling where the needle went in. These typically resolve within a few days to a week. Some people experience mild bruising at the injection site, similar to what happens with other injected medications. Serious infections at the injection site are rare but possible, which is why proper injection technique and site care matter.
How to Delete Your Fitbit Account Guide →
Beyond the injection site, some people report headaches, constipation, nausea, or fatigue when starting buprenorphine products. These effects often decrease as your body adjusts to the medication over the first few weeks. Constipation is common enough that many programs recommend staying ahead of it by increasing fiber, drinking more water, and staying active. If constipation becomes problematic, your provider can suggest over-the-counter options or other interventions.
Buprenorphine can affect your sleep, either causing drowsiness or, less commonly, insomnia. This usually improves with time, but if it continues, discussing it with your healthcare provider matters. Some people experience dizziness, especially when standing up quickly, which typically fades as treatment continues. Sweating changes, including increased sweating, happen for some people and generally become less noticeable after a few weeks.
One important reality: starting buprenorphine treatment, including Brixadi, feels different from the high of opioids—that's intentional and part of how the medication reduces drug-seeking behavior. Some people experience what's
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.